First 'In Vivo' CRISPR Therapy Succeeds in Phase 3 Trial, Eliminating Rare Disease Attacks

June 2026 marks a watershed moment for genetic medicine. For the first time, a CRISPR gene-editing therapy designed to work directly inside the human body has succeeded in a late-stage clinical trial. The results, published in the New England Journal of Medicine, demonstrate that a single infusion can effectively halt the debilitating symptoms of a rare genetic disorder called hereditary angioedema.[1][2]

Hereditary angioedema, or HAE, is a life-threatening condition characterized by severe, unpredictable swelling in the face, limbs, gastrointestinal tract, and airways. The disease is driven by a genetic mutation that causes the overproduction of bradykinin, a peptide that promotes inflammation and fluid leakage from blood vessels.[2][3]

Historically, patients with HAE have relied on chronic, lifelong prophylactic medications to prevent attacks. While these treatments have improved disease management, they require continuous administration, carry a heavy treatment burden, and still leave many patients vulnerable to breakthrough swelling episodes.[2][4]

Lonvoguran ziclumeran, known clinically as lonvo-z, represents a fundamental shift in how genetic diseases are treated. Developed by Intellia Therapeutics, the drug is administered as a one-time outpatient intravenous infusion designed to provide a permanent functional cure by targeting the disease at its genetic root.[3][4]

The most significant scientific achievement of lonvo-z is its in vivo delivery mechanism. Previous CRISPR medicines, such as the sickle cell therapy Casgevy, work ex vivo—meaning cells must be extracted from the patient's bone marrow, edited in a laboratory, and then reinfused during a grueling hospitalization.[4][5]

Lonvo-z bypasses this complex process entirely. The therapy packages the CRISPR-Cas9 editing machinery inside microscopic fat bubbles known as lipid nanoparticles. Once infused into the bloodstream, these nanoparticles travel directly to the liver, where they enter the cells and perform the genetic edit on-site.[2][5]

Inside the liver cells, the CRISPR system acts as molecular scissors to inactivate the KLKB1 gene. This specific edit permanently halts the production of prekallikrein, the precursor to the enzyme that triggers the dangerous release of bradykinin, effectively shutting down the biological pathway that causes HAE attacks.[2][3]

The clinical evidence supporting lonvo-z comes from the Phase 3 HAELO trial, a randomized, double-blind study involving 80 patients aged 16 and older. Participants were randomized to receive either a single 50-milligram dose of the CRISPR therapy or a placebo, and were required to halt their standard prophylactic medications to isolate the drug's efficacy.[1][5]

The trial results were definitive. During the primary evaluation period from weeks 5 through 28, patients who received lonvo-z experienced an 87 percent relative reduction in their monthly HAE attack rate. The average number of monthly attacks plummeted to 0.26 in the treated group, compared to 2.10 in the placebo cohort.[1][2]

Beyond simply reducing the frequency of episodes, the therapy eliminated them entirely for a majority of participants. Sixty-two percent of the patients treated with lonvo-z remained completely attack-free and required no further preventative medication during the six-month observation window, a stark contrast to the 11 percent attack-free rate in the placebo group.[2][3]

Safety is a paramount concern for any permanent genetic alteration, but the trial data revealed a highly favorable profile. The most common adverse events were mild to moderate infusion-related reactions, headaches, and fatigue. Crucially, no serious or severe treatment-related adverse events were reported among the patients receiving the active drug.[4][5]

While the Phase 3 data covers a six-month efficacy window, researchers presented supplementary evidence from earlier Phase 1 and 2 trials indicating that the gene edits remain stable. Follow-up data spanning up to four years post-infusion shows that the treatment's protective effects do not wane, reinforcing the prospect of lifelong durability.[5][6]

Armed with this definitive clinical evidence, Intellia Therapeutics has initiated a rolling Biologics License Application with the U.S. Food and Drug Administration. Because the therapy holds a Regenerative Medicine Advanced Therapy designation, the company expects to complete its submission by late 2026, setting the stage for a potential commercial launch in the first half of 2027.[3][4]

If approved, lonvo-z will enter a competitive market currently dominated by chronic therapies like Takeda's Takhzyro and BioCryst's Orladeyo. Biotech analysts suggest that while the clinical efficacy is paradigm-shifting, the drug's commercial success will depend heavily on its pricing model and the willingness of insurers to cover a high-cost, one-time genetic intervention over ongoing pharmacy expenses.[3][4]

Beyond hereditary angioedema, the success of the HAELO trial serves as a critical proof-of-concept for the entire field of precision medicine. By demonstrating that lipid nanoparticles can safely and effectively deliver CRISPR machinery to the liver in humans, researchers have unlocked a scalable delivery platform.[4][6]

This breakthrough paves the way for a new generation of in vivo gene-editing therapies targeting a wide array of liver-mediated genetic disorders, cardiovascular diseases, and metabolic conditions. The era of editing DNA directly within the human body to cure chronic disease has officially moved from theoretical promise to clinical reality.[5][6]